Humacyte, Inc. – NASDAQ:HUMA
Founder-led company
Humacyte stock price today
$1.6
-3.89
-70.9%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 10 hours
Humacyte stock price monthly change
-21.32%
month
Humacyte stock price quarterly change
-21.32%
quarter
Humacyte stock price yearly change
+84.56%
year
Humacyte key metrics
Market Cap | 561.63M |
Enterprise value | 244.95M |
P/E | -31.25 |
EV/Sales | N/A |
EV/EBITDA | -3.88 |
Price/Sales | N/A |
Price/Book | 3.25 |
PEG ratio | -0.31 |
EPS | -1 |
Revenue | N/A |
EBITDA | -89.17M |
Income | -105.70M |
Revenue Q/Q | N/A |
Revenue Y/Y | 710.06% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeHumacyte stock price history
Humacyte stock forecast
Humacyte financial statements
Average Price Target
$8
Potential upside: 399.87%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -22.70M | |
|---|---|---|---|
| Sep 2023 | 0 | -25.99M | |
| Dec 2023 | 10.79M | -25.10M | -232.68% |
| Mar 2024 | 0 | -31.89M |
| Jun 2023 | 168106000 | 106.98M | 63.64% |
|---|---|---|---|
| Sep 2023 | 149385000 | 112.39M | 75.24% |
| Dec 2023 | 128223000 | 114.67M | 89.44% |
| Mar 2024 | 161466000 | 135.31M | 83.8% |
| Jun 2023 | -22.60M | 1.62M | 6.01M |
|---|---|---|---|
| Sep 2023 | -13.00M | -493K | -764K |
| Dec 2023 | -19.05M | -150K | -335K |
| Mar 2024 | -27.34M | -391K | 62.79M |
Humacyte alternative data
| Aug 2023 | 164 |
|---|---|
| Sep 2023 | 164 |
| Oct 2023 | 164 |
| Nov 2023 | 164 |
| Dec 2023 | 164 |
| Jan 2024 | 164 |
| Feb 2024 | 164 |
| Mar 2024 | 164 |
| Apr 2024 | 164 |
| May 2024 | 183 |
| Jun 2024 | 183 |
| Jul 2024 | 183 |
Humacyte other data
5.42%
-6.17%
of HUMA is owned by hedge funds
48
-24
5.58M
-6.35M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 108005 | 191511 |
| Jun 2024 | 8824 | 1285798 |
| Aug 2024 | 5544 | 1803145 |
| Sep 2024 | 0 | 897938 |
| Nov 2024 | 3594 | 3000000 |
| Dec 2024 | 4600 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | CONSTANTINO MICHAEL T. director | Common Stock | 4,600 | $4.39 | $20,180 | ||
Sale | NIKLASON LAURA E director, officer.. | Common Stock | 261,369 | $4.4 | $1,150,024 | ||
Sale | DOUGAN BRADY W director | Common Stock | 261,369 | $4.4 | $1,150,024 | ||
Purchase | NIKLASON LAURA E director, officer.. | Common Stock | 1,797 | $4.44 | $7,979 | ||
Purchase | DOUGAN BRADY W director | Common Stock | 1,797 | $4.44 | $7,979 | ||
Sale | NIKLASON LAURA E director, officer.. | Common Stock | 427,459 | $4.34 | $1,855,172 | ||
Sale | DOUGAN BRADY W director | Common Stock | 427,459 | $4.34 | $1,855,172 | ||
Sale | NIKLASON LAURA E director, officer.. | Common Stock | 811,172 | $4.44 | $3,601,604 | ||
Sale | DOUGAN BRADY W director | Common Stock | 811,172 | $4.44 | $3,601,604 | ||
Option | GREEN CHARLES BRUCE director | Stock Options (right to buy) | 1,200 | $4.09 | $4,908 |
| Quarter | Transcript |
|---|---|
| Q1 2024 10 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 22 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 10 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 14 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Dr. Jeffrey H. Lawson M.D., Ph.D. (1964) Chief Surgical Officer & Director | $693,890 |
| Dr. Laura E. Niklason M.D., Ph.D. (1963) Founder, Pres, Chief Executive Officer & Director | $556,280 |
Dr. Heather Ledbetter Prichard Ph.D. (1978) Chief Operating Officer | $463,700 |
| Mr. Dale A. Sander (1960) Chief Financial Officer, Chief Corporation Devel. Officer & Treasurer | $97,620 |
The 'Undercovered' Dozen From May 2024
Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
Humacyte: Upcoming BLA, Pivotal Data, Decent Cash, Excellent Opportunity
Humacyte: Major Catalysts Ahead, Solid Prospects, Low Prices
Humacyte: With 2 BLAs Ahead, Solid Cash, Current Lows Make It Undervalued
Humacyte: Intriguing Potential
-
What's the price of Humacyte stock today?
One share of Humacyte stock can currently be purchased for approximately $1.6.
-
When is Humacyte's next earnings date?
Unfortunately, Humacyte's (HUMA) next earnings date is currently unknown.
-
Does Humacyte pay dividends?
No, Humacyte does not pay dividends.
-
How much money does Humacyte make?
Humacyte has a market capitalization of 561.63M.
-
What is Humacyte's stock symbol?
Humacyte, Inc. is traded on the NASDAQ under the ticker symbol "HUMA".
-
What is Humacyte's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Humacyte?
Shares of Humacyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Humacyte's key executives?
Humacyte's management team includes the following people:
- Dr. Jeffrey H. Lawson M.D., Ph.D. Chief Surgical Officer & Director(age: 61, pay: $693,890)
- Dr. Laura E. Niklason M.D., Ph.D. Founder, Pres, Chief Executive Officer & Director(age: 62, pay: $556,280)
- Dr. Heather Ledbetter Prichard Ph.D. Chief Operating Officer(age: 47, pay: $463,700)
- Mr. Dale A. Sander Chief Financial Officer, Chief Corporation Devel. Officer & Treasurer(age: 65, pay: $97,620)
-
Is Humacyte founder-led company?
Yes, Humacyte is a company led by its founder Dr. Laura E. Niklason M.D., Ph.D..
-
How many employees does Humacyte have?
As Jul 2024, Humacyte employs 183 workers, which is 12% more then previous quarter.
-
When Humacyte went public?
Humacyte, Inc. is publicly traded company for more then 4 years since IPO on 1 Dec 2020.
-
What is Humacyte's official website?
The official website for Humacyte is humacyte.com.
-
Where are Humacyte's headquarters?
Humacyte is headquartered at 2525 East North Carolina Highway 54, Durham, NC.
-
How can i contact Humacyte?
Humacyte's mailing address is 2525 East North Carolina Highway 54, Durham, NC and company can be reached via phone at +91 93139633.
-
What is Humacyte stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Humacyte in the last 12 months, the avarage price target is $8. The average price target represents a 399.87% change from the last price of $1.6.
Humacyte company profile:
Humacyte, Inc.
humacyte.comExchange:
NASDAQ
Full time employees:
183
Industry:
Biotechnology
Sector:
Healthcare
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.
2525 East North Carolina Highway 54
Durham, NC 27713
Durham, NC 27713
CIK: 0001818382
ISIN: US44486Q1031
CUSIP: 44486Q103
